文献速递前列腺癌前列腺增生与排尿功能障碍

局限性前列腺癌男性中前列腺体积、基线排尿功能及其与治疗选择和治疗后排尿功能的关联

Prostate volume, baseline urinary function, and their association with treatment choice and post-treatment urinary function in men treated for localized prostate cancer.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2022-12-08

研究基于CEASAR多中心前瞻性队列1647例局限性前列腺癌男性,评估前列腺体积(PV)和基线排尿功能与治疗选择及治疗后排尿功能的关系,随访至5年。未观察到PV与治疗选择或治疗后排尿功能存在有临床意义的关联;基线排尿功能差者接受放疗或手术后6个月排尿功能有统计学和临床显著改善并持续至5年(5年时较基线改善:放疗20.4分,手术24.5分)。

要点

  • 中位基线PV为36 mL(IQR 27-48),基线排尿刺激/梗阻域评分为87(IQR 75-100)。
  • 未观察到PV与治疗选择或治疗后排尿功能存在有临床意义的关联。
  • 基线排尿功能差者接受放疗或手术后6个月排尿功能显著改善并持续至5年。

核心结论

  • 在局限性前列腺癌男性中,未发现PV与治疗方式或治疗后排尿刺激/梗阻功能相关。
  • 基线排尿刺激/梗阻功能差者在手术或放疗后改善。

研究设计与样本

  • 多中心人群为基础的前瞻性队列研究CEASAR,纳入1647例局限性前列腺癌男性进行分析。
  • 主要结局为治疗选择和健康相关生活质量(HRQOL),采用26条目扩展前列腺指数综合量表(EPIC-26)在预设时间点评估至5年。
  • 采用多变量分析,控制人口学和临床病理特征。

主要发现

  • 中位基线PV为36 mL(IQR 27-48),基线排尿刺激/梗阻域评分为87(IQR 75-100)。
  • 未观察到PV与治疗选择或治疗后排尿功能之间存在有临床意义的关联。
  • 基线排尿功能差者接受放疗或手术在6个月时排尿功能有统计学和临床显著改善,并持续至5年(5年时较基线改善:放疗20.4分,手术24.5分)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Benign prostatic hyperplasia, lower urinary tract symptoms, and prostate cancer often co-occur. Their effect on urinary function is an important consideration regarding prostate cancer treatment choices. While prostate volume (PV) and urinary symptoms are commonly used in treatment choice decision making, their association with post-treatment urinary function is unknown. We evaluated the associations between PV and baseline urinary function with treatment choice and post-treatment urinary function among men with localized prostate cancer. METHODS: We identified 1647 patients from CEASAR, a multicenter population-based, prospective cohort study of men with localized prostate cancer, for analysis. Primary outcomes were treatment choice and health-related quality of life (HRQOL) assessed by the 26-item Expanded Prostate Index Composite (EPIC-26) at pre-specified intervals up to 5 years. Multivariable analysis was performed, controlling for demographic and clinicopathologic features. RESULTS: Median baseline PV was 36 mL (IQR 27-48), and baseline urinary irritative/obstructive domain score was 87 (IQR 75-100). There was no observed clinically meaningful association between PV and treatment choice or post-treatment urinary function. Among patients with poor baseline urinary function, treatment with radiation or surgery was associated with statistically and clinically significant improvement in urinary function at 6 months which was durable through 5 years (improvement from baseline at 5 years: radiation 20.4 points, surgery 24.5 points). CONCLUSIONS: PV was not found to be associated with treatment modality or post-treatment urinary irritative/obstructive function among men treated for localized prostate cancer. Men with poor baseline urinary irritative/obstructive function improve after treatment with surgery or radiation therapy.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Tallman JE, Wallis CJD, Zhao Z, et al. Prostate volume, baseline urinary function, and their association with treatment choice and post-treatment urinary function in men treated for localized prostate cancer. Prostate Cancer Prostatic Dis. 2022. PMID: 36482081. doi:10.1038/s41391-022-00627-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。